Risk of ovarian cancer in women with pelvic inflammatory disease: A population-based study

Hui Wen Lin, Ying Yueh Tu, Shiyng-Yu Lin, Wei Ju Su, Wei-Li Lin, Wei Zer Lin, Shen Chi Wu, Yuen-Liang Lai

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Background: Ovarian cancer is commonly fatal and incidence has persistently risen in Taiwan over the past 20 years. Prevention strategies, however, are limited. Pelvic inflammatory disease (PID) has been suggested to increase the risk of developing ovarian cancer, but the results of studies have been inconsistent. Therefore, we investigated whether PID increases the risk of developing ovarian cancer in a large, nationwide cohort. Methods: From the Longitudinal Health Insurance Database 2005 (LHID2005) in Taiwan, we obtained data for women aged 13-65 years for whom a diagnosis of PID, confirmed by multiple episodes, had been recorded between Jan 1, 2004, and Dec 31, 2005. We also obtained data for two controls per patient, matched for age and the year of first entry into the LHID2005. All patients were followed up from the date of entry in the LHID2005 until they developed ovarian cancer or to the end of 2006, whichever was earlier. We used Cox's regression models to assess the risk of developing ovarian cancer, with adjustment for age, comorbid disorders, and socioeconomic characteristics. Findings: We identified 67 936 women with PID and 135 872 controls. Among these 90 had developed ovarian cancer during the 3-year follow-up period (42 patients with PID and 48 controls, incidence 2·78 and 1·44 per 10 000 person-years, respectively). The adjusted hazard ratio for ovarian cancer in patients with PID was 1·92 (95% CI 1·27-2·92) compared with controls, which rose to 2·46 (1·48-4·09) in women who had had at least five episodes of PID. The adjusted hazard ratio was slightly higher for women aged 35 years or younger with PID than in older women with PID (2·23, 1·02-4·79 vs 1·82, 1·10-3·04). Interpretation: We found an association between PID and ovarian cancer. PID might, therefore, be a useful marker for ovarian cancer, and early treatment could help to improve prognosis. Whether pelvic inflammation itself accelerates the growth of ovarian cancers or affects cancer-cell differentiation in ways that adversely alter prognosis needs to be investigated. Funding: None.

Original languageEnglish
Pages (from-to)900-904
Number of pages5
JournalThe Lancet Oncology
Volume12
Issue number9
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Pelvic Inflammatory Disease
Ovarian Neoplasms
Population
Health Insurance
Databases
Taiwan
Incidence
Proportional Hazards Models
Cell Differentiation

ASJC Scopus subject areas

  • Oncology

Cite this

Risk of ovarian cancer in women with pelvic inflammatory disease : A population-based study. / Lin, Hui Wen; Tu, Ying Yueh; Lin, Shiyng-Yu; Su, Wei Ju; Lin, Wei-Li; Lin, Wei Zer; Wu, Shen Chi; Lai, Yuen-Liang.

In: The Lancet Oncology, Vol. 12, No. 9, 09.2011, p. 900-904.

Research output: Contribution to journalArticle

Lin, Hui Wen ; Tu, Ying Yueh ; Lin, Shiyng-Yu ; Su, Wei Ju ; Lin, Wei-Li ; Lin, Wei Zer ; Wu, Shen Chi ; Lai, Yuen-Liang. / Risk of ovarian cancer in women with pelvic inflammatory disease : A population-based study. In: The Lancet Oncology. 2011 ; Vol. 12, No. 9. pp. 900-904.
@article{1c0454b20e9c4ddfaab7160425354f2f,
title = "Risk of ovarian cancer in women with pelvic inflammatory disease: A population-based study",
abstract = "Background: Ovarian cancer is commonly fatal and incidence has persistently risen in Taiwan over the past 20 years. Prevention strategies, however, are limited. Pelvic inflammatory disease (PID) has been suggested to increase the risk of developing ovarian cancer, but the results of studies have been inconsistent. Therefore, we investigated whether PID increases the risk of developing ovarian cancer in a large, nationwide cohort. Methods: From the Longitudinal Health Insurance Database 2005 (LHID2005) in Taiwan, we obtained data for women aged 13-65 years for whom a diagnosis of PID, confirmed by multiple episodes, had been recorded between Jan 1, 2004, and Dec 31, 2005. We also obtained data for two controls per patient, matched for age and the year of first entry into the LHID2005. All patients were followed up from the date of entry in the LHID2005 until they developed ovarian cancer or to the end of 2006, whichever was earlier. We used Cox's regression models to assess the risk of developing ovarian cancer, with adjustment for age, comorbid disorders, and socioeconomic characteristics. Findings: We identified 67 936 women with PID and 135 872 controls. Among these 90 had developed ovarian cancer during the 3-year follow-up period (42 patients with PID and 48 controls, incidence 2·78 and 1·44 per 10 000 person-years, respectively). The adjusted hazard ratio for ovarian cancer in patients with PID was 1·92 (95{\%} CI 1·27-2·92) compared with controls, which rose to 2·46 (1·48-4·09) in women who had had at least five episodes of PID. The adjusted hazard ratio was slightly higher for women aged 35 years or younger with PID than in older women with PID (2·23, 1·02-4·79 vs 1·82, 1·10-3·04). Interpretation: We found an association between PID and ovarian cancer. PID might, therefore, be a useful marker for ovarian cancer, and early treatment could help to improve prognosis. Whether pelvic inflammation itself accelerates the growth of ovarian cancers or affects cancer-cell differentiation in ways that adversely alter prognosis needs to be investigated. Funding: None.",
author = "Lin, {Hui Wen} and Tu, {Ying Yueh} and Shiyng-Yu Lin and Su, {Wei Ju} and Wei-Li Lin and Lin, {Wei Zer} and Wu, {Shen Chi} and Yuen-Liang Lai",
year = "2011",
month = "9",
doi = "10.1016/S1470-2045(11)70165-6",
language = "English",
volume = "12",
pages = "900--904",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - Risk of ovarian cancer in women with pelvic inflammatory disease

T2 - A population-based study

AU - Lin, Hui Wen

AU - Tu, Ying Yueh

AU - Lin, Shiyng-Yu

AU - Su, Wei Ju

AU - Lin, Wei-Li

AU - Lin, Wei Zer

AU - Wu, Shen Chi

AU - Lai, Yuen-Liang

PY - 2011/9

Y1 - 2011/9

N2 - Background: Ovarian cancer is commonly fatal and incidence has persistently risen in Taiwan over the past 20 years. Prevention strategies, however, are limited. Pelvic inflammatory disease (PID) has been suggested to increase the risk of developing ovarian cancer, but the results of studies have been inconsistent. Therefore, we investigated whether PID increases the risk of developing ovarian cancer in a large, nationwide cohort. Methods: From the Longitudinal Health Insurance Database 2005 (LHID2005) in Taiwan, we obtained data for women aged 13-65 years for whom a diagnosis of PID, confirmed by multiple episodes, had been recorded between Jan 1, 2004, and Dec 31, 2005. We also obtained data for two controls per patient, matched for age and the year of first entry into the LHID2005. All patients were followed up from the date of entry in the LHID2005 until they developed ovarian cancer or to the end of 2006, whichever was earlier. We used Cox's regression models to assess the risk of developing ovarian cancer, with adjustment for age, comorbid disorders, and socioeconomic characteristics. Findings: We identified 67 936 women with PID and 135 872 controls. Among these 90 had developed ovarian cancer during the 3-year follow-up period (42 patients with PID and 48 controls, incidence 2·78 and 1·44 per 10 000 person-years, respectively). The adjusted hazard ratio for ovarian cancer in patients with PID was 1·92 (95% CI 1·27-2·92) compared with controls, which rose to 2·46 (1·48-4·09) in women who had had at least five episodes of PID. The adjusted hazard ratio was slightly higher for women aged 35 years or younger with PID than in older women with PID (2·23, 1·02-4·79 vs 1·82, 1·10-3·04). Interpretation: We found an association between PID and ovarian cancer. PID might, therefore, be a useful marker for ovarian cancer, and early treatment could help to improve prognosis. Whether pelvic inflammation itself accelerates the growth of ovarian cancers or affects cancer-cell differentiation in ways that adversely alter prognosis needs to be investigated. Funding: None.

AB - Background: Ovarian cancer is commonly fatal and incidence has persistently risen in Taiwan over the past 20 years. Prevention strategies, however, are limited. Pelvic inflammatory disease (PID) has been suggested to increase the risk of developing ovarian cancer, but the results of studies have been inconsistent. Therefore, we investigated whether PID increases the risk of developing ovarian cancer in a large, nationwide cohort. Methods: From the Longitudinal Health Insurance Database 2005 (LHID2005) in Taiwan, we obtained data for women aged 13-65 years for whom a diagnosis of PID, confirmed by multiple episodes, had been recorded between Jan 1, 2004, and Dec 31, 2005. We also obtained data for two controls per patient, matched for age and the year of first entry into the LHID2005. All patients were followed up from the date of entry in the LHID2005 until they developed ovarian cancer or to the end of 2006, whichever was earlier. We used Cox's regression models to assess the risk of developing ovarian cancer, with adjustment for age, comorbid disorders, and socioeconomic characteristics. Findings: We identified 67 936 women with PID and 135 872 controls. Among these 90 had developed ovarian cancer during the 3-year follow-up period (42 patients with PID and 48 controls, incidence 2·78 and 1·44 per 10 000 person-years, respectively). The adjusted hazard ratio for ovarian cancer in patients with PID was 1·92 (95% CI 1·27-2·92) compared with controls, which rose to 2·46 (1·48-4·09) in women who had had at least five episodes of PID. The adjusted hazard ratio was slightly higher for women aged 35 years or younger with PID than in older women with PID (2·23, 1·02-4·79 vs 1·82, 1·10-3·04). Interpretation: We found an association between PID and ovarian cancer. PID might, therefore, be a useful marker for ovarian cancer, and early treatment could help to improve prognosis. Whether pelvic inflammation itself accelerates the growth of ovarian cancers or affects cancer-cell differentiation in ways that adversely alter prognosis needs to be investigated. Funding: None.

UR - http://www.scopus.com/inward/record.url?scp=80052380558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052380558&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(11)70165-6

DO - 10.1016/S1470-2045(11)70165-6

M3 - Article

C2 - 21835693

AN - SCOPUS:80052380558

VL - 12

SP - 900

EP - 904

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 9

ER -